Vir Biotechnology Reports Positive Phase 3 Trial Results for Chronic Hepatitis Delta Treatment
Vir Biotechnology (VIR) announced that its experimental combination therapy successfully met its primary endpoint in a Phase 3 clinical trial targeting chronic hepatitis delta. The study indicates significant progress toward developing an effective treatment for the virus. Additionally, data from separate Phase 2 trials demonstrated sustained viral suppression in patients even after discontinuing the treatment. These results suggest the potential for long-term efficacy and could represent a major step toward a functional cure for the disease.